Pharmafile Logo

Glaucoma in perspective

- PMLiVE

Pfizer’s Talzenna combination shows promise in phase 3 prostate cancer study

10-20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

Facts are stubborn things

California tried to tell doctors what would be classified as misinformation – it didn’t go well

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how #innovative medical devices and software can improve...

Impetus Digital

- PMLiVE

Impetus Digital’s Virtual Learning Programs named PM360’s Most Innovative Services of 2022

About the AwardToronto, ON, December 15, 2022 — PM360, a leading trade magazine for marketing decision-makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Impetus Digital’s Virtual...

Impetus Digital

- PMLiVE

Merck KGaA and Aqilion AB partner in potential €960m deal

The companies will work together to develop small molecule inhibitors of the TAK1 protein

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

Ipsen to acquire worldwide rights to pre-clinical stage oncology programme

The company has an existing partnership with the Université de Montréal and IRICoR

- PMLiVE

GSK and Vir Biotech amend COVID-19 research partnership

Vir will now advance new antibodies and vaccines for COVID-19 alone or with other partners

- PMLiVE

Changing an organisation’s microfoundations – why capabilities count

Today and tomorrow, it’s what you can and can’t do that counts

- PMLiVE

End-to-end patient strategy: Making a treatment for patients, with patients

The integration of patient engagement in all stages of a product lifecycle is starting to become much more commonplace and you may start to hear the term end-to-end patient strategy...

Origins – The Patient Focused Specialists

Biogen Idec building

Safety-related change to label for Biogen’s Alzheimer’s drug Aduhelm approved by FDA

Larger areas of bleeding on the brain have been reported in some patients taking the drug

- PMLiVE

SMC enables access to Kyowa Kirin’s Crysvita for adults with rare genetic disease

XLH is a life-long genetic disease that causes abnormalities in the bones, muscles and joints

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links